Pharmafile Logo

News and Press Releases

Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease

Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025

Redx Pharma
info@redxpharma.com
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases

DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation,...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

Domain Therapeutics
contact@domaintherapeutics.com
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France

AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis

Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...

Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025

AbbVie
AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

Mage Biologics announces first subject dosed in a phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 19, 2024

Tillotts Pharma
tillotts@tillotts.com
Baslerstrasse 15 CH-4310 Rheinfelden Switzerland

Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease

12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024

Tillotts Pharma
tillotts@tillotts.com
Baslerstrasse 15 CH-4310 Rheinfelden Switzerland

SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases

12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

ModeX Therapeutics Leverages ProBioGen’s Expertise for Accelerated COVID-19 Antibody Development

29 May 2024 -- Berlin, Germany -- ProBioGen, a leading contract development and manufacturing organisation (CDMO), known for its innovative solutions in cell engineering and bioprocessing excellence, announces a pivotal...

Category: BioManufacturing, Biotechnology, Pharmaceutical
Posted: May 29, 2024

ModeX Therapeutics
info@modextx.com
20 Riverside Road Weston, MA 02493